FRA:BIO - Deutsche Boerse Ag - DE0005227201 - Common Stock - Currency: EUR
FRA:BIO (5/28/2025, 7:00:00 PM)
42.8
-0.2 (-0.47%)
The current stock price of BIO.DE is 42.8 EUR. In the past month the price increased by 4.9%. In the past year, price increased by 0.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.08 | 288.63B | ||
AMG.DE | AMGEN INC | 13.56 | 133.33B | ||
GIS.DE | GILEAD SCIENCES INC | 14.08 | 119.43B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 102.00B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 13.82 | 58.22B | ||
ARGX.BR | ARGENX SE | 107.98 | 31.05B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.85B | ||
IDP.DE | BIOGEN INC | 8.23 | 16.80B | ||
1BMRN.MI | BIOMARIN PHARMACEUTICAL INC | 34 | 9.98B | ||
0QF.DE | MODERNA INC | N/A | 9.09B | ||
1MRNA.MI | MODERNA INC | N/A | 9.06B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.70B |
Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
BIOTEST AG
Landsteinerstr. 5
Dreieich HESSEN DE
Employees: 2495
Phone: 4961038010
The current stock price of BIO.DE is 42.8 EUR. The price decreased by -0.47% in the last trading session.
The exchange symbol of BIOTEST AG is BIO and it is listed on the Deutsche Boerse Ag exchange.
BIO.DE stock is listed on the Deutsche Boerse Ag exchange.
BIOTEST AG (BIO.DE) has a market capitalization of 1.69B EUR. This makes BIO.DE a Small Cap stock.
BIOTEST AG (BIO.DE) currently has 2495 employees.
BIOTEST AG (BIO.DE) has a support level at 42.7 and a resistance level at 43.01. Check the full technical report for a detailed analysis of BIO.DE support and resistance levels.
The Revenue of BIOTEST AG (BIO.DE) is expected to grow by 11.95% in the next year. Check the estimates tab for more information on the BIO.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BIOTEST AG (BIO.DE) has a dividend yield of 0.09%. The yearly dividend amount is currently 0.04. Check the full fundamental report for a detailed analysis of BIO.DE dividend history, reliability and sustainability.
BIOTEST AG (BIO.DE) will report earnings on 2025-08-04.
The PE ratio for BIOTEST AG (BIO.DE) is 65.85. This is based on the reported non-GAAP earnings per share of 0.65 and the current share price of 42.8 EUR. Check the full fundamental report for a full analysis of the valuation metrics for BIO.DE.
ChartMill assigns a technical rating of 6 / 10 to BIO.DE. When comparing the yearly performance of all stocks, BIO.DE turns out to be only a medium performer in the overall market: it outperformed 47.45% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to BIO.DE. BIO.DE has only an average score on both its financial health and profitability.
Over the last trailing twelve months BIO.DE reported a non-GAAP Earnings per Share(EPS) of 0.65. The EPS decreased by -74% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 3.64% | ||
ROA | 1.84% | ||
ROE | 4.97% | ||
Debt/Equity | 1.2 |
ChartMill assigns a Buy % Consensus number of 46% to BIO.DE. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 1600% and a revenue growth 11.95% for BIO.DE